Prostate SABR

Fast, Precise, Effective


SABR is an advanced 5-day radiation treatment for prostate cancer. For many patients, it is an excellent alternative to conventional radiation therapy, which can take up to 45 sessions. Read on or contact us for information on one of our upcoming FREE informational seminars and see if SABR is right for you.

Prostate SABR

Fast, Precise, Effective

SABR is an advanced 5-day radiation treatment for prostate cancer. For many patients, it is an excellent alternative to conventional radiation therapy, which can take up to 45 sessions. Read on or contact us for information on one of our upcoming FREE informational seminars and see if SABR is right for you.

Prostate SABR

Fast, Precise, Effective

SABR is an advanced 5-day radiation treatment for prostate cancer. For many patients, it is an excellent alternative to conventional radiation therapy, which can take up to 45 sessions. Read on or contact us for information on one of our upcoming FREE informational seminars and see if SABR is right for you.

Token Distribution

BENEFITS OF SABR

(Stereotactic Ablative Body Radiation)


SABR (Stereotactic Ablative Body Radiation, also known as Stereotactic Body Radiation Therapy – SBRT) is a treatment technique that uses precisely targeted, very high dose x-ray beams to destroy small cancers. First developed in the early 2000s as an alternative to surgery for treatment of small lung cancers, it has since been proven to be highly effective and safe in the treatment of a wide variety of cancer types throughout the body, including prostate cancer.

How long has SABR been used for prostate cancer?

SABR has been used to treat prostate cancer since 2003. Since this time the technique has been continually refined since this time based upon published data of both safety and efficacy.

How effective is prostate SABR?

Published data from multiple centers throughout the world have demonstrated SABR to be at least as effective as conventional 45-day treatment. For more detailed review of the data supporting prostate SABR, please see References .

Is prostate SABR safe?

Yes. There is a substantial body of peer-reviewed data demonstrating that the safety of prostate SABR is at least equivalent, if not superior, to that of conventional radiation therapy.For more detailed review of the data supporting prostate SABR, please see References .

Why isn’t prostate SABR available at more radiation centers?

Safe and effective delivery of prostate SABR requires state-of-the-art linear accelerator technology, intensive medical physics support, and specialized physician expertise. Few community-based centers at present have this combination of attributes.

Is it feasible to be treated with SABR if I live outside of central Florida?

Yes. Special arrangements to facilitate the consultation, treatment planning, and treatment delivery process to meet out-of-town patients’ needs can be made as needed.

Token Distribution

How does SABR differ from conventional radiation therapy for prostate cancer?


SABR differs from conventional radiation therapy for prostate cancer (also known as IMRT) in several significant ways.

  • 1) Duration Treatment takes only 5 sessions instead of up to 45 sessions.
  • 2) Margins The prescription dose of radiation is distributed more tightly around the prostate gland
  • 3) Setup Patients are positioned in a more intricate manner
  • 4) Preparation Patients have a more rigorous bowel and bladder preparation prior to each session
  • Prostate SABR - 5 Days
  • Traditional Radiation Therapy - 45 Days

SABR TREATMENT PROCESS


The SABR treatment process is similar to, but more accelerated than traditional radiation therapy. We’ll take you through the steps from consultation to follow-up so you can see what the journey is like.

CONSULTATION

CONSULTATION

Dr. Brabham will review and discuss your case with you and determine whether SABR is an appropriate treatment option for your prostate cancer.

STAGING SCANS

STAGING SCANS

If appropriate and not already performed, Dr. Brabham will order imaging studies to determine the clinical stage of your prostate cancer.

PLACEMENT OF FIDUCIAL MARKERS

PLACEMENT OF FIDUCIAL MARKERS

Three, small plastic markers called fiducials will be placed in the patient’s prostate in a procedure which is similar to a prostate biopsy, but quicker and typically much less uncomfortable. These markers will be imaged during each treatment to ensure precise positioning of the prostate to allow for on-target dose delivery.

TREATMENT PLANNING CT SCAN

TREATMENT PLANNING CT SCAN

During this session, the patient’s custom body mold will be created and a CT scan of the patient in this device will be performed immediately thereafter. Patients prepare for the scan with a self-administered enema to achieve an empty rectum and by drinking a moderate amount of water prior to the procedure to achieve a full bladder.

PROSTATE MRI

PROSTATE MRI

MRI of the prostate will be performed shortly after the CT simulation to generate the highest resolution images possible of the prostate and the surrounding anatomy. The MRI images will then be combined with the images from CT simulation, allowing Dr. Brabham to produce a highly accurate three-dimensional model of the patient’s anatomy to be used in treatment planning.

TREATMENT DELIVERY

TREATMENT DELIVERY

Treatment delivery typically occurs within one to two weeks of the treatment planning scans. Each treatment takes approximately 10 minutes of set-up time and approximately 2 minutes of radiation delivery time. Treatment is non-invasive and entirely painless. Patients perform the same bladder and rectal preparation as for the treatment planning scan.

FOLLOW-UP AFTER TREATMENT

FOLLOW-UP AFTER TREATMENT

After treatment you will follow up periodically in this clinic for PSA monitoring and overall clinical assessment.

Get in Touch

What SABR Patients are Saying


To visit our primary site, click below

To schedule a SABR consultation,
Call Florida Oncology Tavares at

Get in Touch

REFERENCES

Kupelian P, Mehta NH, King C, et al. Stereotactic body radiation therapy for prostate cancer: Rational and reasonable. Pract Radiat Oncol 2015;5:188-192.

Evans JR, Zhao S, Daignault S, et al. Patient-reported quality of life after stereotactic body radiation therapy (SBRT), intensity modulated radiotherapy (IMRT), and brachytherapy. Radiother Oncol 2015;116: 179-184.

Bhattasali O, Chen LN, Woo J, et al. Patient-reported outcomes following stereotactic body radiation therapy for clinically localized prostate cancer. Radiat Oncol 2014;9:52.

King CR, Freeman D, Kaplan I, et al. Stereotactic body radiotherapy for localized prostate cancer: Pooled analysis from a multiinstitutional consortium of prospective phase II trials. Radiother Oncol 2013;109:217-221.

Meier R. Dose-escalated robotic SBRT for stage I-II prostate cancer. Front Oncol 2015;5:48.

Katz AJ, Santoro M, Diblasio F, et al. Stereotactic body radiotherapy for localized prostate cancer: Disease control and quality of life at 6 years. Radiat Oncol 2013;8:118.

King CR, Brooks JD, Gill H, Presti Jr JC. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2012;82:877-882.

Oliai C, Lanciano R, Sprandio B, et al. Stereotactic body radiation therapy for the primary treatment of localized prostate cancer. J Radiat Oncol. 2013;2:63-70.

McBride SM, Wong DS, Dombrowski JJ, et al. Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: Preliminary results of a multi-institutional phase 1 feasibility trial. Cancer. 2012;118:3681-3690.

Boike TP, Lotan Y, Cho LC, et al. Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer. J Clin Oncol. 2011;29:2020-2026.

Kang JK, Cho CK, Choi CW, et al. Image-guided stereotactic body radiation therapy for localized prostate cancer. Tumori. 2011;97:43-48.

Freeman DE, King CR. Stereotactic body radiotherapy for low-risk prostate cancer: Five-year outcomes. Radiat Oncol. 2011;6:3.

Bolzicco G, Favretto MS, Scremin E, Tambone C, Tasca A, Guglielmi R. Image-guided stereotactic body radiation therapy for clinically localized prostate cancer: Preliminary clinical results. Technol Cancer Res Treat. 2010;9:473-477.

Katz AJ, Santoro M, Ashley R, Diblasio F, Witten M. Stereotactic body radiotherapy for organ-confined prostate cancer. BMC Urol. 2010;10:1.

Friedland JL, Freeman DE, Masterson-McGary ME, Spellberg DM. Stereotactic body radiotherapy: An emerging treatment approach for localized prostate cancer. Technol Cancer Res Treat. 2009;8:387-392.

REFERENCES

Kupelian P, Mehta NH, King C, et al. Stereotactic body radiation therapy for prostate cancer: Rational and reasonable. Pract Radiat Oncol 2015;5:188-192.

Evans JR, Zhao S, Daignault S, et al. Patient-reported quality of life after stereotactic body radiation therapy (SBRT), intensity modulated radiotherapy (IMRT), and brachytherapy. Radiother Oncol 2015;116: 179-184.

Bhattasali O, Chen LN, Woo J, et al. Patient-reported outcomes following stereotactic body radiation therapy for clinically localized prostate cancer. Radiat Oncol 2014;9:52.

King CR, Freeman D, Kaplan I, et al. Stereotactic body radiotherapy for localized prostate cancer: Pooled analysis from a multiinstitutional consortium of prospective phase II trials. Radiother Oncol 2013;109:217-221.

Meier R. Dose-escalated robotic SBRT for stage I-II prostate cancer. Front Oncol 2015;5:48.

Katz AJ, Santoro M, Diblasio F, et al. Stereotactic body radiotherapy for localized prostate cancer: Disease control and quality of life at 6 years. Radiat Oncol 2013;8:118.

King CR, Brooks JD, Gill H, Presti Jr JC. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2012;82:877-882.

Oliai C, Lanciano R, Sprandio B, et al. Stereotactic body radiation therapy for the primary treatment of localized prostate cancer. J Radiat Oncol. 2013;2:63-70.

McBride SM, Wong DS, Dombrowski JJ, et al. Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: Preliminary results of a multi-institutional phase 1 feasibility trial. Cancer. 2012;118:3681-3690.

Boike TP, Lotan Y, Cho LC, et al. Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer. J Clin Oncol. 2011;29:2020-2026.

Kang JK, Cho CK, Choi CW, et al. Image-guided stereotactic body radiation therapy for localized prostate cancer. Tumori. 2011;97:43-48.

Freeman DE, King CR. Stereotactic body radiotherapy for low-risk prostate cancer: Five-year outcomes. Radiat Oncol. 2011;6:3.

Bolzicco G, Favretto MS, Scremin E, Tambone C, Tasca A, Guglielmi R. Image-guided stereotactic body radiation therapy for clinically localized prostate cancer: Preliminary clinical results. Technol Cancer Res Treat. 2010;9:473-477.

Katz AJ, Santoro M, Ashley R, Diblasio F, Witten M. Stereotactic body radiotherapy for organ-confined prostate cancer. BMC Urol. 2010;10:1.

Friedland JL, Freeman DE, Masterson-McGary ME, Spellberg DM. Stereotactic body radiotherapy: An emerging treatment approach for localized prostate cancer. Technol Cancer Res Treat. 2009;8:387-392.